Who Owns Otrivin?
Otrivin is owned by Haleon plc, a publicly traded British consumer healthcare company that was spun off from GSK in July 2022. Otrivin was originally developed by Ciba-Geigy (now part of Novartis) and introduced in 1966. The brand transferred to GSK's consumer health division in 2014 as part of a major asset swap with Novartis, and became part of Haleon when GSK spun off its consumer health business in 2022.
Parent Company
Haleon plc
Acquired
2014
Status
Publicly Traded
Headquarters
Weybridge, United Kingdom
Who Owns Otrivin?
- Parent Company: Haleon plc
- Ownership Type: Wholly owned
- Acquisition Year: 2014
- Company Type: Publicly Traded
- Stock Ticker: LSE: HLN
| Brand | Parent Company | Ownership Type |
|---|---|---|
| Otrivin | Haleon plc | Wholly owned |
History of Otrivin
- Founded: 1966
- Founders: Ciba-Geigy (now Novartis)
- Acquired by Haleon plc: 2014
Otrivin was developed by Ciba-Geigy researchers and introduced in 1966 as an over-the-counter nasal decongestant spray. The active ingredient, xylometazoline hydrochloride, is a topical vasoconstrictor that provides rapid relief from nasal congestion by reducing swelling in the nasal passages. The drug represented a significant advancement in nasal congestion treatment, offering fast-acting relief within minutes of application.
Throughout the 1970s and 1980s, Otrivin became one of the most widely recognized nasal decongestant brands globally, particularly in Europe, Asia, and Latin America. The brand expanded its product line to include formulations for adults and children, as well as moisturizing variants to reduce nasal dryness. Otrivin became a household name in many countries for cold and allergy symptom relief.
When Novartis was formed through the merger of Ciba-Geigy and Sandoz in 1996, Otrivin became part of Novartis's consumer health portfolio. The brand continued to expand its global presence and product range under Novartis ownership.
In 2014, Otrivin transferred to GSK's consumer healthcare joint venture as part of a major restructuring deal between Novartis and GSK. GSK took full control of the venture in 2018. In July 2022, Otrivin became part of Haleon plc when GSK spun off its consumer healthcare division. Under Haleon, Otrivin continues to be marketed in over 50 countries as a trusted nasal decongestant.
About Haleon plc
What does Haleon own?
Haleon owns a portfolio of approximately 24 global and regional consumer health brands across five categories: oral health, vitamins and supplements, pain relief, respiratory health, and digestive health. Key brands include Sensodyne (sensitivity toothpaste), Panadol (pain relief), Centrum (multivitamins), Advil (ibuprofen), Voltaren (topical pain relief), Otrivin (nasal decongestant), Parodontax (gum health), Polident and Poligrip (denture care), Aquafresh (oral care), and Emergen-C (vitamin C). Products are sold in more than 170 countries.
Is Haleon publicly traded?
Yes, Haleon plc is listed on the London Stock Exchange under ticker HLN, with American Depositary Shares also listed on the New York Stock Exchange under the same ticker. Haleon completed its listing on the London Stock Exchange on 18 July 2022, in what was the largest London Stock Exchange listing in over a decade. The company does not have a controlling shareholder, and its shares are held primarily by institutional investors.
Who founded Haleon?
Haleon was formed through the demerger of GSK's consumer healthcare division in July 2022 and does not have a traditional founder. The consumer healthcare business that became Haleon was assembled by GSK and Pfizer through decades of acquisitions. In 2019, GSK and Pfizer combined their consumer healthcare businesses into a joint venture, which was subsequently demerged as Haleon in 2022. Brian McNamara, who had led the GSK Consumer Healthcare joint venture, became CEO of Haleon at the time of the demerger.
Where is Haleon headquartered?
Haleon is headquartered in Weybridge, Surrey, United Kingdom. The company's registered office and principal executive offices are located in Weybridge. Haleon operates manufacturing facilities in the United Kingdom, the United States, India, Germany, Ireland, and China, among other locations. The company sells products in more than 170 countries through a global commercial organization.
How many brands does Haleon own?
Haleon owns approximately 24 global and regional consumer health brands. The company's portfolio is concentrated in five categories: oral health (Sensodyne, Parodontax, Polident, Poligrip, Aquafresh), vitamins and supplements (Centrum, Caltrate, Emergen-C), pain relief (Advil, Panadol, Voltaren), respiratory health (Otrivin, Theraflu, Robitussin), and digestive health (Nexium Control, Tums). The company's strategy is to build global scale in a small number of category-leading brands rather than operate a large number of smaller brands.
Who owns Haleon?
Haleon plc is a publicly traded company with no controlling shareholder. At the time of the July 2022 demerger, GSK plc and Pfizer Inc. each retained significant stakes in Haleon, but both companies have been reducing their positions over time. As of early 2026, both GSK and Pfizer have substantially reduced their stakes. The remaining shares are held by institutional investors and public shareholders. The company's board includes a majority of independent non-executive directors.
- Founded: 2022
- Headquarters: Weybridge, Surrey, United Kingdom
- Company Type: Publicly Traded
- Stock: LSE: HLN
- Revenue: approximately £10.2 billion (FY2025)
- Employees: Approximately 24,000
Where Is Otrivin Made / Based?
- Headquarters: Weybridge, United Kingdom
- Manufacturing / Operations: United Kingdom, Switzerland, Various international locations
Otrivin Sustainability & Ethics
Otrivin operates within Haleon plc's comprehensive sustainability framework, which focuses on making health more inclusive while reducing environmental impact. As a leading global nasal decongestant brand, Otrivin has implemented specific sustainability initiatives that align with Haleon's ambitious environmental goals.
Climate and Emissions Targets: Haleon has committed to achieving net zero carbon emissions across its value chain by 2040, with specific targets to reduce net Scope 1 and 2 emissions by 100% by 2030 compared to 2020 levels. The company aims to reduce Scope 3 carbon emissions by 42% by 2030 compared to 2022. As of 2024, Haleon achieved a 50% reduction in net Scope 1 and 2 carbon emissions, progress that directly benefits Otrivin's manufacturing and distribution footprint.
Sustainable Packaging Innovation: Otrivin has pioneered sustainable packaging solutions in the nasal spray category. In 2023, Haleon launched Otrivin products featuring 52% bio-based material pumps developed in partnership with Aptar Pharma. This innovation supports Haleon's goal to reduce virgin petroleum-based plastic use by 10% by 2025 and by a third by 2030 compared to 2022 levels. The bio-based pumps represent a significant advancement in pharmaceutical packaging sustainability.
Recycle-Ready Packaging Initiative: Otrivin participates in Haleon's goal to make all packaging recyclable or reusable by 2030, with all packaging to be recycle-ready by 2025. The brand is transitioning to mono-material packaging and removing problematic plastics like PVC to ensure compatibility with existing recycling infrastructure. Otrivin's paper-based packaging is sourced from recycled or certified sources to support deforestation-free supply chains by 2030.
Supply Chain Ethics and Responsible Sourcing: Haleon maintains comprehensive supply chain ethics programs that extend to Otrivin manufacturing. The company requires suppliers to adhere to strict environmental and labor standards, conducting regular audits to verify compliance. Haleon's responsible sourcing program focuses on protecting worker rights, ensuring safe working conditions, and preventing forced labor throughout the consumer healthcare supply chain.
Product Innovation and Sustainability: The 2023 launch of Otrivin Nasal Mist represents the brand's commitment to combining product innovation with sustainability. The new microdroplet technology, developed through a seven-year collaboration with Aptar Pharma, provides enhanced comfort while utilizing more sustainable packaging materials. The Lateral Control System technology improves the user experience while reducing environmental impact.
Environmental Compliance and Stewardship: Otrivin manufacturing facilities operate under strict environmental management systems, with Haleon implementing programs to reduce water consumption, minimize waste, and improve energy efficiency across production sites. The company's environmental policy ensures compliance with all relevant regulations while pursuing continuous improvement in environmental performance.
Awards & Recognition
Otrivin has received recognition for its market leadership, product innovation, and sustainability initiatives in the consumer healthcare sector. The brand's long-standing presence and continued innovation have earned it accolades from industry organizations and healthcare publications.
Market Leadership Recognition: Otrivin was ranked as the world's #1 non-prescription nasal decongestant spray in 2022, demonstrating its dominant market position in the respiratory health category. This recognition reflects the brand's global reach and consumer trust built over nearly 60 years of providing effective nasal congestion relief.
Packaging Innovation Awards: The 2023 launch of Otrivin Nasal Mist with Aptar Pharma's Lateral Control System technology received industry recognition for innovation in pharmaceutical packaging. The microdroplet technology and 52% bio-based material pump represent significant advancements in nasal spray delivery systems and sustainable packaging design.
WorldStar Global Packaging Award: In 2026, Otrivin's innovative packaging received a WorldStar Global Packaging Award, recognizing excellence in packaging design and sustainability. The award specifically highlighted the brand's use of bio-based materials and innovative delivery technology that improves both user experience and environmental performance.
Healthcare Industry Recognition: Otrivin has been acknowledged by healthcare professionals and consumer health organizations for its role in advancing nasal decongestant technology. The brand's commitment to research and development in nasal health has been recognized as contributing to improved treatment options for nasal congestion sufferers.
Sustainability Leadership: As part of Haleon's portfolio, Otrivin contributes to the company's recognition as one of the world's most sustainable companies. Haleon was ranked #34 in Sustainability Magazine's Top 250 World's Most Sustainable Companies 2025, with Otrivin's sustainable packaging initiatives cited as a key example of the company's environmental leadership.
Otrivin Recalls & Controversies
Otrivin has maintained a strong safety record throughout its nearly 60-year history, with no major product recalls reported. However, like all nasal decongestant products containing xylometazoline, the brand faces ongoing scrutiny regarding proper usage and potential side effects.
Medication Overuse Concerns: The primary controversy surrounding Otrivin and similar nasal decongestants is the risk of rebound congestion (rhinitis medicamentosa) when used beyond the recommended 5-7 day period. Healthcare professionals have raised concerns about consumers developing dependency on nasal sprays, leading to chronic congestion issues. This has resulted in increased educational efforts by Haleon to promote proper usage guidelines.
Regulatory Compliance: Otrivin has maintained compliance with regulatory requirements across all markets where it operates. The active ingredient xylometazoline hydrochloride is approved for over-the-counter use in most countries, though dosage regulations vary by region. No significant regulatory actions have been taken against Otrivin for safety or efficacy issues.
Cardiovascular Safety Monitoring: As with all vasoconstrictor medications, Otrivin carries warnings for patients with certain cardiovascular conditions, including hypertension, heart disease, and thyroid disorders. The brand includes comprehensive contraindication information on packaging and in patient information leaflets. No major safety incidents related to cardiovascular effects have been reported.
Pediatric Usage Guidelines: Otrivin has faced scrutiny regarding appropriate usage in children, leading to the development of specific pediatric formulations with lower concentrations of xylometazoline. The brand maintains clear age-specific usage guidelines and has worked with healthcare professionals to ensure proper pediatric administration.
Environmental Impact Discussions: Some environmental groups have raised concerns about the environmental impact of nasal spray propellants and packaging. Haleon has addressed these concerns through the development of more sustainable packaging options, including the 2023 introduction of bio-based material pumps for Otrivin products.
Competition from Natural Alternatives: Otrivin faces ongoing market challenges from increasing consumer preference for natural and non-medicated congestion relief options, including saline nasal sprays and herbal remedies. This has led to expanded product offerings, including non-medicated nasal hygiene products under the Otrivin brand.
Brands Owned by Haleon plc
Otrivin Ownership: Pros & Cons
Advantages
- +Fast-acting nasal decongestant providing relief within minutes
- +Available over-the-counter in most markets for convenient access
- +Trusted brand reputation built over nearly 60 years
- +Multiple formulations for adults, children, and sensitive users
- +Strong global distribution through Haleon's pharmacy and retail networks
Considerations
- -Risk of rebound congestion (rhinitis medicamentosa) with prolonged use beyond 5-7 days
- -Potential for nasal irritation or dryness in some users
- -Not suitable for patients with certain cardiovascular conditions
- -Competition from saline sprays and natural decongestant alternatives
- -Some consumers prefer non-medicated congestion relief options
Frequently Asked Questions About Otrivin
Sources & Further Reading
- Haleon Official Website -
- Haleon Sustainability Report 2025 -
- Otrivin Nasal Mist Launch Announcement -
- Haleon Annual Report and Form 20-F 2025 -
- Sustainability Magazine: Haleon Recycle-Ready Packaging -
- Healthcare Packaging: Otrivin Bio-based Material Launch -
- London Stock Exchange: Haleon plc (HLN) -
- NYSE: Haleon plc (HLN) -
- WorldStar Packaging Awards -
- Consumer Healthcare Products Association -
Where to Buy
Disclosure: We may earn commission from purchases
Otrivin on AmazonCompetitors to Otrivin
These competing brands operate in the same categories and provide similar products or services. Compare key attributes to understand market positioning and competitive landscape.
| Brand | Parent Company | Country | Founded | Market Position | Primary Market | Gender Target |
|---|---|---|---|---|---|---|
| Pfizer | USA | 1990 | Mass market | Global | All-ages | |
| Haleon | United Kingdom | 1976 | Mass market | Global | All-ages | |
| Johnson Johnson | USA | 1946 | Mass market | Global | All-ages | |
| Kenvue | USA | 1974 | Mass market | Global | All-ages | |
| Johnson Johnson | USA | 1972 | Mass market | Global | All-ages | |
| Merck | USA | 1986 | Mass market | Global | All-ages |
Learn More About Competitors
Diflucan
Owned by Pfizer
Prescription antifungal medication for treating fungal infections including candidiasis and cryptococcal meningitis, manufactured and marketed by Pfizer.
Voltaren
Owned by Haleon plc
Over-the-counter anti-inflammatory pain relief brand containing diclofenac, owned by Haleon plc (LSE/NYSE: HLN) since its July 2022 spinoff from the GSK and Pfizer consumer health joint venture, with Voltaren growing mid-single digit in full-year 2025 supported by new format patches and Voltadexibu launches.
Benadryl
Owned by Johnson & Johnson
American brand of antihistamine medication used to treat allergies, itching, and cold symptoms, manufactured and marketed by Johnson & Johnson.
Motrin
Owned by Kenvue
American brand of ibuprofen pain relief medication owned by Kenvue, the consumer health spinoff from Johnson & Johnson, which is being acquired by Kimberly-Clark in a $40 billion deal announced in November 2025.
Neosporin
Owned by Johnson & Johnson
American brand of antibiotic ointment and topical wound care products containing triple antibiotic formula, manufactured and marketed by Johnson & Johnson.
Pepcid
Owned by Merck & Co.
Over-the-counter and prescription medication for treating heartburn and acid reflux, manufactured and marketed by Merck & Co.
Competitive Analysis
Market Positioning: Otrivin competes with 6 brands in the same categories, ranging from mass market to luxury positioning.
Geographic Distribution: Competitors are headquartered across multiple regions, indicating global competition in this market segment.
Brand Heritage: Competitor brands range from established heritage brands to newer market entrants, with founding years spanning several decades.
Haleon plc Stock Information
Jobs at Haleon plc
Latest News About Otrivin
Related Articles About Otrivin
View more articles
Who Owns the Toothpaste Market
Colgate, Procter & Gamble, Unilever, and GSK (now Haleon) together control the global toothpaste market. Here is a full breakdown of which companies own which toothpaste brands, and how this market became one of the most concentrated in consumer goods.
Pharmaceutical Brand Ownership: A Complete Guide
Who makes your medications? Discover which corporations own the biggest pharmaceutical brands, from Ozempic to Tylenol, and how pharma M&A affects you.
Brand Spin-offs: When Companies Sell Off Their Own Brands
From Kenvue to Kellanova, major corporations are spinning off iconic brands into independent companies. Learn why, how it works, and what it means for consumers.
People Also Searched
Discover popular brands and companies in the Healthcare & Pharmaceuticals category and related searches from other users.
Activase
Prescription thrombolytic medication for treating acute myocardial infarction and stroke, manufactured and marketed by Roche.
Acuvue
Johnson & Johnson's contact lens brand, launched in 1988 as the world's first disposable contact lens and now the global market leader in daily disposable lenses.
Adcetris
Prescription antibody-drug conjugate for treating Hodgkin lymphoma and other CD30-positive lymphomas, manufactured and marketed by Takeda Pharmaceutical Company.